Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04310410
Other study ID # NL68441.041.19
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date April 11, 2019
Est. completion date June 1, 2020

Study information

Verified date February 2024
Source UMC Utrecht
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PRE-FURTHER study aims to evaluate the feasibility of the combined treatment with radiotherapy and focussed ultrasound for pain palliation in patients with painful bone metastases, and to optimize the combined treatment logistics. Six to ten patients will be included according to in- and exclusion criteria.


Description:

Rationale: Metastatic bone pain strongly interferes with quality of life and daily functioning of patients with advanced cancer. Pain palliation may be improved by including magnetic resonance image guided high intensity focused ultrasound (MR-HIFU) in addition to External Beam Radiotherapy (EBRT). For this purpose, feasibility and optimal logistics of the combined treatment need to be evaluated. Objective: The PRE-FURTHER project aims to evaluate the feasibility of the combined EBRT and MR-HIFU treatment for relief of metastatic bone pain, and to optimize the combined treatment logistics. Study design: The PRE-FURTHER study is a prospective case series, stage I and IIA study according to the Innovation, Development, Evaluation, Assessment and Long term evaluation (IDEAL) recommendations. 6-10 patients will receive MR-HIFU treatment following standard EBRT. Endpoints: The main outcome of this study is the feasibility of the procedure, in terms of planability as well as patient-tolerability of the combined treatment within a short time frame (3 hours - 4 days interval). In addition, pain relief and safety of the combined procedure will be monitored.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date June 1, 2020
Est. primary completion date April 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women with age = 18 years - Patient capable of giving informed consent and able to attend study visits - Uncomplicated painful bone metastases - Weight <140kg and able to fit in the MRI gantry - Radiologic evidence of bone metastases from any solid tumor - Pain is localized to the targeted area, or is likely to be referred pain arising from the targeted area - Pain related to the target lesion is refractory to less invasive treatments for pain relief - Multiple metastatic lesions, with one predominantly painful lesion (>=2 points higher pain score than other lesions). The lesion should be clearly distinguishable from other painful lesions. - Device accessible tumors: extremities (excluding joints), pelvis, shoulders, posterior vertebral spine below L5, in selected cases ribs and sternum - Target lesion maximum dimension = 8cm - Intended target volume visible by non-contrast MR imaging - Distance between target and skin = 1cm - Numeric Rating Scale (NRS) score >= 4 or equivalent - Life expectancy >3 months Exclusion Criteria: - Planned treatment lesion is a primary bone tumor or due to lymphoma, multiple myeloma, or leukemia. - Communication barrier present - Patient enrolled in another clinical study related to bone metastases treatment or pain relief treatment - Unable to tolerate required stationary position during treatment despite adequate pain medication - Need for surgery - Pregnant woman - Pain related to target lesion is predominantly due to fracture or impending fracture - Pain related to target lesion is due to involvement of a neighboring major nerve by the metastatic tumor (cord or nerve compression) - Target < 3cm from bladder / bowel / nerve along the beam path and < 1cm in the plane orthogonal to the beam - Target in contact with hollow viscera - Target located in skull, joints, ribs (when HIFU beam overlapping with lung), spine (excluding sacrum which is allowed) or in most cases sternum - Internal or external fixation device along the proposed HIFU beam path or at the target - MRI contraindicated (e.g. paramagnetic implants, pacemaker, claustrophobia) - MRI contrast agent contraindicated (e.g. previous anaphylaxis or Glomerular Filtration Rate < 20 ml/min/1.73m2) - Sedation contraindicated - Previous surgery or minimally invasive treatment at targeted site within the last three months - Clinically relevant medical history or abnormal physical findings that could interfere with the safety of the participant as judged by the treating physician or investigator - Karnofsky performance score (KPS) < 60% - Oligometastatic disease planned for curative treatment - Indication for stereotactic radiotherapy (e.g. patients with radioresistant histology such as renal cell, melanoma, sarcoma metastases) - History of photodermatoses (of the skin overlying the target area) - Need for remineralisation

Study Design


Intervention

Combination Product:
combined radiotherapy and MR-HIFU
Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.

Locations

Country Name City State
Netherlands University Medical Center Utrecht Utrecht
Netherlands Isala Klinieken Zwolle Zwolle Overijsel

Sponsors (2)

Lead Sponsor Collaborator
UMC Utrecht Isala

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of combined treatment with EBRT and MR-HIFU - Patient tolerance: questionnaire The main outcome of this study is the feasibility of the combined procedure in terms of patient tolerance and hospital logistics. Patient tolerance will be assessed using a Patient Reported Experience Measure questionnaire. 4 weeks
Primary Feasibility of combined treatment with EBRT and MR-HIFU - hospital logistics The main outcome of this study is the feasibility of the combined procedure in terms of patient tolerance and hospital logistics. Hospital logistics will be assessed by analysing comments of the treating physicians and research staff on the problems that occurred during treatment planning, and whether extra hospital visits that were needed. 4 weeks
Secondary Patient reported pain scores. Patient reported pain scores will be based on a Numeric Rating Scale (from 0 to 10 with 0 being no pain and 10 being the worst pain imaginable) from the Brief Pain Inventory (BPI) questionnaire [Cleeland 1994]. at 3 days, and at 1, 2, 3 and 4 weeks
Secondary (Serious) adverse events Toxicity/safety of the combined treatment will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at 3 days, and at 1, 2, 3 and 4 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care